New Epinephrine Injection Launched in Retail Pharmacies
Published Online: Tuesday, July 9th, 2019
The retail launch of Sandoz’ epinephrine (Symjepi) 0.3 mg and 0.15 mg injections was announced today. The launch makes adult and pediatric doses immediately available in local pharmacies across the United States.
Granted FDA approval in 2018, both doses of this product were made available in hospitals and clinics earlier this year.
Sandoz’ 0.3 mg and 0.15 mg injections are indicated for the emergency treatment of allergic reactions including anaphylaxis to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances and other allergens, as well as idiopathic or exercise-induced anaphylaxis.
“Our collaboration with retail partners will enable patients and their caregivers to conveniently access Symjepi, a cost-effective treatment option with a compact and user-friendly design,” said Carol Lynch, President of Sandoz Inc, a division of Novartis, in a prepared statement.
The 0.3 mg and 0.15 mg injections are intended for immediate administration in patients who weigh approximately 66 pounds or more, and who weigh between 33 and 65 pounds, respectively, who are determined to be at an increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions. These epinephrine products are small, single-dose, pre-filled syringes and device combinations that provide an alternative to epinephrine auto-injectors.
Ongoing shortages of epinephrine auto-injectors from several drug manufacturers have been highlighted by the FDA. Health care providers should prescribe “epinephrine injection” rather than “epinephrine auto-injector” to ensure pharmacies provide epinephrine medicine alternatives during their first attempt to fill their prescription, according to Sandoz.
RELATED ARTICLES
Reference
Sandoz extends SYMJEPI™ (epinephrine) Injection launch to US pharmacies to help improve patient access to life-saving medicine [news release]. Princeton, NJ; July 9, 2019: Sandoz website. https://www.us.sandoz.com/news/media-releases/sandoz-extends-symjepi-epinephrine-injection-launch-us-pharmacies-help-improve. Accessed July 9, 2019.
Granted FDA approval in 2018, both doses of this product were made available in hospitals and clinics earlier this year.
Sandoz’ 0.3 mg and 0.15 mg injections are indicated for the emergency treatment of allergic reactions including anaphylaxis to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances and other allergens, as well as idiopathic or exercise-induced anaphylaxis.
“Our collaboration with retail partners will enable patients and their caregivers to conveniently access Symjepi, a cost-effective treatment option with a compact and user-friendly design,” said Carol Lynch, President of Sandoz Inc, a division of Novartis, in a prepared statement.
The 0.3 mg and 0.15 mg injections are intended for immediate administration in patients who weigh approximately 66 pounds or more, and who weigh between 33 and 65 pounds, respectively, who are determined to be at an increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions. These epinephrine products are small, single-dose, pre-filled syringes and device combinations that provide an alternative to epinephrine auto-injectors.
Ongoing shortages of epinephrine auto-injectors from several drug manufacturers have been highlighted by the FDA. Health care providers should prescribe “epinephrine injection” rather than “epinephrine auto-injector” to ensure pharmacies provide epinephrine medicine alternatives during their first attempt to fill their prescription, according to Sandoz.
RELATED ARTICLES
- Generic Epinephrine Auto-Injector Available to Hospitals, Clinics
- FDA Grants Fast Track Designation to Epinephrine Nasal Spray
Reference
Sandoz extends SYMJEPI™ (epinephrine) Injection launch to US pharmacies to help improve patient access to life-saving medicine [news release]. Princeton, NJ; July 9, 2019: Sandoz website. https://www.us.sandoz.com/news/media-releases/sandoz-extends-symjepi-epinephrine-injection-launch-us-pharmacies-help-improve. Accessed July 9, 2019.
Current Issue
The Educated Patient
Exposure to damp and moly environments may also result in a variety of other health issues.
An accurate medical history and a physical exam are critical to rule out more serious conditions.
Practitioners should get a detailed medical history and conduct a thorough physical to treat sinus infections.
Providing them with advice can improve control of the disease and reduce hospitalizations, morbidity, and unscheduled health care visits.